

MyoPax Denmark ApS

Ole Maaløes Vej 3 2200 København N CVR no. 43 07 80 46

Annual report for 2023

1		11 1		
2	ANIC	diatual	621	

MyoPax Denmark ApS Annual report 2023 CVR-nr. 43 07 80 46

Table of contents

Page
1
2
5
6
7
10
11
13
14

Statement by management on the annual report

The Board of Directors and executive board have today discussed and approved the annual report of MyoPax Denmark ApS for the financial year 1 January - 31 December 2023.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2023 and of the results of the company's operations for the financial year 1 January - 31 December 2023.

In our opinion, management's review includes a fair review of the matters dealt with in the management's review.

Management recommends that the annual report should be approved by the company in general meeting.

Copenhagen, 4 June 2024

Executive board

Verena Jennifer Johanna Schöwel-Wolf

U. Schowel - Wolf

Board of Directors

Simone Spuler

J. pule

Verena Jennifer Johanna Schöwel-Wolf

(). Showel-wolf

Independent auditor's report

To the Shareholders of MyoPax Denmark ApS Opinion

We have audited the financial statements of MyoPax Denmark ApS for the financial year 1 January - 31 December 2023, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared under the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2023 and of the results of the company's operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements, that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Independent auditor's report

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on management's review

Management is responsible for management's review.

Our opinion on the financial statements does not cover management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Independent auditor's report

Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.

Frederikssund, 4 June 2024

LPOG ApS Statsautoriserede Revisorer CVR no. 33 16 72 88

Anders Pedersen State Authorised Public Accountant mne34550

Company details

The company	MyoPax Denmark ApS Ole Maaløes Vej 3 2200 København N		
	CVR no.:	43 07 80 46	
	Reporting period: Incorporated:	1 January - 31 December 2023 22 February 2022	
	Domicile:	Copenhagen	
Board of Directors	Simone Spuler Verena Jennifer Johanna Schöwel-Wolf		
Executive board	Verena Jennifer Johanna Schöwel-Wolf		
Auditors	LPOG ApS Statsautoriserede Revisorer Kilde Alle 22, 3. sal 3600 Frederikssund		

Management's review

Business review

The Company's objects are development, production and distribution of therapeutics for the treatment of muscle defects and generalized muscle wasting, including genetic muscle diseases.

Financial review

The company's income statement for the year ended 31 December 2023 shows a loss of DKK 5.320.286, and the balance sheet at 31 December 2023 shows negative equity of DKK 7.268.147.

The company has lost more than 50% of the company capital and is therefore covered by the capital loss provisions of the Companies Act. At the upcoming general meeting, the management will give an account of the financial situation and present that the company capital is expected to be reestablished in the event of future capital increases.

For information regarding the company's capital resources, please refer to the information in note 1.

Significant events occurring after the end of the financial year

No events have occurred after the balance sheet date which could significantly affect the company's financial position.

Anvendt regnskabspraksis

The annual report of MyoPax Denmark ApS for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to reporting class B entities, as well as provisions applying to reporting class C entities.

The accounting policies applied are consistent with those of last year.

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Income statement

Gross profit

In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue.

Gross profit reflects an aggregation of other operating income less costs of raw materials and consumables and other external expenses.

Raw materials and consumables

Costs of raw materials and consumables include the raw materials and consumables used in generating the year's revenue.

Other operating income

The item other operating income includes items of a secondary nature relative to the company's activities, including gains on the sale of equipment, grants, as well as payroll refunds.

Other external expenses

Other external costs include expenses related to sale, advertising, administration, premises etc.

Anvendt regnskabspraksis

Staff costs

Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts that relate to the financial year. Net financials include interest income and expenses.

Tax on profit/loss for the year

Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the year and directly in equity as regards the portion that relates to entries directly in equity.

Balance sheet

Receivables

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable is impaired, an impairment loss for that individual asset is recognised.

Cash and cash equivalents

Cash and cash equivalents comprise cash and deposits at banks.

Income tax and deferred tax

Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.

Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively. Deferred tax is measured at net realisable value.

Anvendt regnskabspraksis

Liabilities

Loans are recognised initially at the proceeds received net of transaction expenses incurred. Subsequently, the loans are measured at amortised cost; the difference between the proceeds and the nominal value is recognised as an interest expense in the income statement over the loan period.

Other debts are measured at amortised cost, substantially corresponding to nominal value.

Resultatopgørelse 1 January - 31 December

	Note	2023 DKK	2022 тдкк
Gross profit		-4.852.720	-1.832
Staff costs	2	-1.114.039	-325
Profit/loss before net financials		-5.966.759	-2.157
Financial costs	3	-373.546	-94
Profit/loss before tax		-6.340.305	-2.251
Tax on profit/loss for the year	4	1.020.019	263
Profit/loss for the year	-	-5.320.286	-1.988
Recommended appropriation of profit/loss			

Retained earnings -5.320.286 -1.988 -5.320.286 -1.988

Balance 31 December

	Note	<u>2023</u> 	2022 TDKK
Assets			
Other receivables		55.817	99
Corporation tax		1.020.019	263
Receivables		1.075.836	362
Cash at bank and in hand		2.275.275	2.203
Total current assets		3.351.111	2.565
Total assets		3.351.111	2.565

Balance 31 December

	Note	2023	2022
		DKK	TDKK
Equity and liabilities			
Share capital		40.000	40
Retained earnings		-7.308.147	-1.988
Equity		-7.268.147	-1.948
Convertible and profit-yielding instruments of debt		10.461.960	4.089
Total non-current liabilities	5	10.461.960	4.089
Trade payables		144.724	371
Other payables		12.574	53
Total current liabilities		157.298	424
Total liabilities		10.619.258	4.513
Total equity and liabilities		3.351.111	2.565
Uncertainty about the continued operation (going concern) Contingent liabilities	1 6		
Mortgages and collateral	7		

Statement of changes in equity

	Retained		
	Share capital	earnings	Total
Equity	40.000	-1.987.861	-1.947.861
Net profit/loss for the year	0	-5.320.286	-5.320.286
Equity	40.000	-7.308.147	-7.268.147

Notes

1 Uncertainty about the continued operation (going concern)

The company has lost more than half of its capital and the equity is negative with DKK 7.268.147.

The company's liquidity for 2024 is sufficient to maintain the company's operating activities and the company can continue to fulfill its obligations as they are due. Furthermore, the company will in 2024 start to approach more funding to expand the activities.

2	Staff assts	<u>2023</u> DKК	2022 TDKK
2	Staff costs		
	Wages and salaries	944.808	287
	Other social security costs	169.231	38
		1.114.039	325
		2	1
	Number of fulltime employees on average	2	1
3	Financial costs Other financial costs Exchange loss	372.659	94
		373.546	94
4	Tax on profit/loss for the year Current tax for the year	-1.020.019	-263
		-1.020.019	-263

Notes

5 Long term debt

	Debt at 1 January 2023	Debtat 31 December 2023	Instalment next year	Debt outstanding after 5 years
Convertible and profit-yielding instruments of debt	4.089.315	10.461.960	0	0
	4.089.315	10.461.960	0	0

Convertible loan, with a nominal value of DKK 10.440 thousand, are convertible into shares at the prevailing market price with a conversion discount ranging from 0-30%, depending on the timing of conversion.

Of the long-term liabilities, DKK 0 falls due for payment after more than 5 years after the balance sheet date.

MyoPax Denmark ApS Annual report 2023 CVR-nr. 43 07 80 46

Notes

6 Contingent liabilities

The company has entered into a lease with the following amounts.

Term to maturity in 3 months with an average payment of DKK 3 thousand, totalling DKK 9 thousand.

7 Mortgages and collateral

The Company has no mortgages and collateral.